Intracorporeal medicaments for photodynamic treatment of disease
New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection. In another preferred embodiment, such medicaments are produced in various formulations including liquid, semisolid, solid or aerosol delivery vehicles.
1 - 44 . (canceled)
45 . A method comprising:
providing a halogenated xanthene selected from the group consisting of Erythrosin B, Phloxine B, and Rose Bengal in a dosage form suitable for use as a medicament for intravenous, intramuscular, intratumoral or transcutaneous delivery; and
providing instructions to use said medicament for photodynamic treatment of diseased human tissue, said diseased human tissue comprising cancerous or pre-cancerous lesions, dermatologic disease, or bacterial infection, using light applied to said diseased human tissue at an intensity of 200 mW/cm 2 or less.
46 . A method comprising:
providing a halogenated xanthene selected from the group consisting of Erythrosin B, Phloxine B, and Rose Bengal in a dosage form suitable for use as a medicament for per oesophageal or intracavitary administration; and
providing instructions to use said medicament for photodynamic treatment of diseased human tissue, said diseased human tissue comprising cancerous or pre-cancerous lesions, dermatologic disease, or bacterial infection, using light applied to said diseased human tissue at an intensity of 200 mW/cm 2 or less.
47 . A method of treating cancerous or pre-cancerous lesions, dermatologic disease, or bacterial infection of human tissue comprising:
providing a dosage unit of a sterile intracorporeal photodynamic medicament consisting of an aqueous solution of a sodium, potassium or lithium salt of a halogenated xanthene, wherein said halogenated xanthene is a compound selected from the group consisting of Erythrosin B, Phloxine B, and Rose Bengal; and
providing instructions for use of said medicament for photodynamic treatment of said diseased human tissue using light applied to said diseased human tissue at an intensity of 200 mW/cm 2 or less.
48 . A method of treating cancerous or pre-cancerous lesions, dermatologic disease, or bacterial infection of human tissue comprising:
providing a dosage unit of an intracorporeal photodynamic medicament consisting of a capsule, a suppository, a syrup, or a micro-droplet spray containing a halogenated xanthene, wherein said halogenated xanthene is a compound selected from the group consisting of Erythrosin B, Phloxine B, and Rose Bengal; and
providing instructions for use of said medicament for photodynamic treatment of said diseased human tissue using light applied to said diseased human tissue at an intensity of 200 mW/cm 2 or less.